

Special Issue

HPV Vaccination Coverage: Problems and Challenges

Message from the Guest Editors

Human papillomavirus (HPV) infection is highly prevalent, and high-risk HPV strains can cause cervical, oropharyngeal, anal, vaginal, penile, and vulvar cancers. Cervical cancer is the fourth most common cancer among women worldwide, and oropharyngeal cancer (OPC) prevalence has only been rising. Moreover, OPCs are 2–5 times more common among men than women. HPV vaccines are safe and effective and can prevent over 90% of these cancers, but their uptake is suboptimal. Thus, improving HPV vaccination is essential to reduce mortality and morbidity due to HPV-associated cancers and related inequities. There are various national and global objectives aligned to increase HPV vaccination rates. As a result, these have seen improvement over the years. However, they still remain significantly lower than regularly required vaccines, pointing to unique challenges specific to the HPV vaccine. This Special Issue therefore aims to discuss these challenges at various levels across settings, geography, and populations, as well as identify strategies to improve HPV vaccine availability, distribution, and uptake.

Guest Editors

Dr. Shillpa Naavaal

Dr. Zheng Quan Toh

Dr. Paul Licciardi

Deadline for manuscript submissions

closed (30 April 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/204820

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).